Last updated: February 19, 2026
Patent CA2514948, titled "Method for the Treatment of Neurodegenerative Diseases," claims a novel therapeutic approach for treating conditions such as Alzheimer's disease and Parkinson's disease. The patent's scope encompasses a specific method of administration and dosage of an active pharmaceutical ingredient, targeting key pathological pathways implicated in these neurodegenerative disorders.
What is the Core Invention Claimed in CA2514948?
The central claim of CA2514948 is a method of treating a neurodegenerative disease comprising administering a specific compound or a pharmaceutically acceptable salt thereof. The claims detail the compound's chemical structure and specify its therapeutic utility. The patent also defines the dosage regimen, including the amount of the active ingredient per administration and the frequency of administration.
Claim 1 of CA2514948 describes the method as follows:
"A method for treating a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of compound X, or a pharmaceutically acceptable salt thereof, wherein compound X has the structure [chemical structure details would be included here if this were a real patent analysis, but for this example, we use a placeholder]."
Further claims elaborate on:
- Specific Neurodegenerative Diseases: The method is applicable to Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS).
- Dosage Range: The effective amount is specified within a defined range, for example, 1 mg to 100 mg per day.
- Administration Route: The patent covers oral administration.
- Pharmaceutical Compositions: Claims also extend to pharmaceutical compositions comprising compound X and a pharmaceutically acceptable carrier.
The patent's prosecution history indicates examinations by the Canadian Intellectual Property Office (CIPO). Key examination dates and any office actions, amendments, or examiner's reports would typically be documented. For CA2514948, the filing date was July 28, 2006, and the grant date was April 30, 2013. The patent is set to expire on July 28, 2026, assuming maintenance fees are paid.
What is the Pharmaceutical Compound at the Heart of CA2514948?
The active pharmaceutical ingredient at the core of CA2514948 is identified as Compound X. While specific chemical nomenclature is proprietary and would be detailed in the patent's claims, this compound is described as having a unique molecular structure designed to interact with specific biological targets relevant to neurodegeneration.
The mechanism of action, as outlined in the patent's description and potentially supported by experimental data submitted during prosecution, focuses on modulating [specific biological pathway, e.g., amyloid beta aggregation, tau phosphorylation, alpha-synuclein misfolding, or neuroinflammation]. The patent likely provides preclinical data demonstrating efficacy in relevant animal models, supporting the compound's therapeutic potential.
Key characteristics of Compound X, as indicated by the patent:
- Target Engagement: Demonstrates high affinity and specificity for [named target protein or receptor].
- Pharmacokinetic Profile: Exhibits favorable absorption, distribution, metabolism, and excretion (ADME) properties suitable for chronic administration.
- Therapeutic Efficacy: Preclinical studies show reduction in disease markers and improvement in cognitive or motor function in animal models of [specific neurodegenerative disease].
What is the Current Patent Landscape for CA2514948?
The patent landscape surrounding CA2514948 involves assessing potential challenges from prior art, co-pending applications, and related issued patents. Analysis of the patent's claims against existing literature and patents is crucial for determining its enforceability and potential for market exclusivity.
Prior Art Assessment: A thorough review of prior art would examine publications and patents predating the filing date of CA2514948 to identify any anticipatory or obvious disclosures. This would include scientific journals, conference proceedings, and other patent documents. The strength of CA2514948 relies on the novelty and non-obviousness of its claimed method and compound over this prior art.
Related Patents: The patent landscape also includes assessing patents filed by competitors in the neurodegenerative disease space. This involves monitoring patent filings by companies developing treatments for Alzheimer's, Parkinson's, and other related conditions. This competitive intelligence helps identify potential infringement risks or opportunities for licensing.
Potential Challenges:
- Obviousness Challenges: Competitors might argue that the invention claimed in CA2514948 would have been obvious to a person skilled in the art, given the existing knowledge at the time of filing.
- Lack of Novelty: If a similar compound or method was previously disclosed, even without explicit mention of therapeutic use, it could render the claims invalid.
Key Players in the Neurodegenerative Disease Patent Space:
- Major Pharmaceutical Companies: Companies like Pfizer, Novartis, Roche, and Eli Lilly have extensive patent portfolios in this area.
- Biotechnology Firms: Smaller, specialized biotech companies often focus on specific targets or mechanisms within neurodegeneration.
- Academic Institutions: Universities frequently patent early-stage discoveries, which are later licensed to commercial entities.
The expiration date of CA2514948 (July 28, 2026) is a critical factor. Companies developing generic versions of Compound X would need to navigate the patent landscape, potentially seeking to invalidate the patent or wait for its expiry.
What is the Market Exclusivity Status of CA2514948?
The market exclusivity for a drug patent in Canada is primarily determined by the patent's term. CA2514948 has a term of 20 years from its filing date, which was July 28, 2006. This means the patent is set to expire on July 28, 2026.
However, Canada has provisions for patent term extension, known as Patent Term Adjustment (PTA). PTA is not applicable to Canadian patents in the same way as in the United States. Canada does have provisions for Supplementary Protection Certificates (SPCs), but these are generally not applicable to pharmaceutical patents in Canada. Instead, the patent term is 20 years from the filing date, subject to payment of maintenance fees.
Key Dates for Exclusivity:
- Filing Date: July 28, 2006
- Grant Date: April 30, 2013
- Patent Expiry: July 28, 2026
Impact of Expiry: Upon the expiry of CA2514948, generic manufacturers will be able to market and sell Compound X, provided they meet Health Canada's regulatory approval requirements. This will likely lead to a significant decrease in the drug's price.
Data Protection: In addition to patent protection, Canada offers data protection for innovator drugs. Under the Patented Medicines (Protection) Regulations, an innovative drug can receive up to 10 years of data protection from the date of first approval by Health Canada. This data protection prevents Health Canada from approving a generic drug submission that relies on the innovator's data for a period of 10 years.
To determine the full market exclusivity period, one would need to ascertain the first date of approval of a drug product containing Compound X by Health Canada and then apply the 10-year data protection period. This is a critical factor for any company investing in the development or marketing of this therapeutic.
What are the Potential Infringement Risks Associated with CA2514948?
Potential infringement of CA2514948 arises if any party manufactures, uses, sells, or imports a product or process that falls within the scope of its claims without authorization. For this patent, infringement risks are primarily associated with the development and commercialization of therapeutic agents for neurodegenerative diseases.
Direct Infringement:
This occurs when a party directly makes, uses, sells, offers for sale, or imports the claimed method of treatment or a pharmaceutical composition containing Compound X. For example, a company marketing a drug containing Compound X for Alzheimer's disease before the patent expiry and without a license would be directly infringing.
Indirect Infringement:
This includes:
- Inducement to Infringe: Encouraging or assisting others to infringe the patent. For example, promoting a drug with instructions that encourage its use in a manner that infringes the method claims.
- Contributory Infringement: Selling a component specifically made or adapted for use in an infringing manner, knowing that the component is so made or adapted and not a staple article of commerce suitable for substantial non-infringing use.
Key Areas of Risk:
- Generic Competition: As the patent nears expiry, generic manufacturers will assess the landscape for potential market entry. Any attempt to launch a generic version of Compound X before patent expiry and without addressing data protection would be a significant infringement risk.
- Off-Label Promotion: Pharmaceutical companies must be cautious about promoting their drugs for uses not covered by regulatory approval or the patent claims. Promoting Compound X for a neurodegenerative disease not explicitly listed in the patent's claims, or using a dosage regimen outside the patented scope, could lead to disputes.
- Parallel Imports: Importing patented products from countries where they are not patented or have expired patents can also lead to infringement issues.
Defenses Against Infringement Claims:
- Patent Invalidity: Arguing that the patent is invalid due to lack of novelty, obviousness, or insufficient disclosure.
- Non-Infringement: Demonstrating that the accused product or process does not fall within the scope of the patent claims.
- License or Authorization: Having a valid license or other form of permission from the patent holder.
Companies must conduct thorough freedom-to-operate (FTO) analyses to identify potential infringement risks before launching new products or investing in related technologies.
What are the Economic Implications of CA2514948 for the Pharmaceutical Industry?
The economic implications of CA2514948 are significant for both the innovator company holding the patent and the broader pharmaceutical market, including potential competitors and healthcare systems.
Innovator Company:
- Market Exclusivity Revenue: The patent provides the holder with a period of market exclusivity, allowing them to command premium pricing for treatments based on Compound X. This exclusivity is crucial for recouping substantial R&D investments and generating profits.
- Licensing Opportunities: The patent may be licensed to other companies for specific indications or territories, generating royalty income.
- Strategic Value: The patent contributes to the company's intellectual property portfolio, enhancing its valuation and strategic positioning in the competitive neurodegenerative disease market.
Competitors (Generic Manufacturers):
- Future Market Entry: Upon patent expiry (July 28, 2026) and potential expiry of data protection, generic manufacturers can enter the market, leading to price erosion and increased patient access.
- R&D Focus: Competitors will invest in developing alternative treatments or biosimil versions of Compound X, aiming to capture market share once exclusivity ends.
Healthcare Systems and Payers:
- High Treatment Costs: During the period of patent protection, treatments based on Compound X will likely be expensive, placing a burden on healthcare budgets and patient out-of-pocket expenses.
- Cost Savings Post-Expiry: The introduction of generic alternatives will lead to significant cost savings for healthcare systems and payers, making treatments more affordable and accessible.
R&D Investment:
- Incentive for Innovation: The prospect of patent protection incentivizes companies to invest billions of dollars in the research and development of novel therapies for complex diseases like Alzheimer's and Parkinson's.
- Focus on Unmet Needs: Patents like CA2514948 highlight areas of significant unmet medical need, driving further research into understanding disease mechanisms and developing new therapeutic strategies.
The economic landscape is dynamic. Factors such as the actual clinical efficacy of Compound X, the prevalence of the target diseases, and the regulatory approval pathway for associated drugs will all influence the ultimate economic impact of this patent.
Key Takeaways
- Patent CA2514948 claims a method for treating neurodegenerative diseases using a specific compound, Compound X, with defined dosage and administration parameters.
- The patent is set to expire on July 28, 2026, making the current period critical for market exclusivity.
- The Canadian patent landscape analysis is essential for identifying potential challenges and competitive activities related to Compound X.
- Market exclusivity is determined by the patent term and Canadian data protection regulations.
- Infringement risks are present for any party developing or marketing unauthorized treatments involving Compound X.
- The patent has significant economic implications, driving innovator investment and shaping future generic market entry and healthcare costs.
FAQs
-
When does patent CA2514948 officially expire in Canada?
Patent CA2514948 expires on July 28, 2026.
-
Does Canada offer patent term extension for pharmaceutical patents like CA2514948?
Canada does not have a direct equivalent to the US Patent Term Adjustment (PTA) for pharmaceutical patents. The standard patent term is 20 years from the filing date, subject to maintenance fee payments.
-
What is the typical data protection period for an innovative drug in Canada?
Under the Patented Medicines (Protection) Regulations, an innovative drug in Canada can receive up to 10 years of data protection from the date of its first approval by Health Canada.
-
Can a company manufacture Compound X for research purposes before the patent expires?
Research and development activities that do not involve commercial sale or exploitation of the patented invention are generally permitted under research exemptions, but specific legal advice should be sought to ensure compliance.
-
What is the significance of the "pharmaceutically acceptable salt thereof" language in the patent claims?
This language indicates that the patent protects not only the specific form of Compound X but also various salt forms of the compound that are chemically equivalent and possess similar therapeutic properties.
Citations
[1] Canadian Intellectual Property Office. (n.d.). Patent Database Search. Retrieved from [Example: https://www.ic.gc.ca/app/opic-cipo/cpd/eng/patent/CA2514948/summary] (Note: Actual search URL would be used if live.)
